Ranke MB: Towards a consensus on the definition of idiopathic short stature.Horm Res 1996,45(Suppl 2):64–6.
Cohen P, Rogol AD, Deal CL, Saenger P, Reiter EO, Ross JL, et al.: Consensus statement on the diagnosis and treatment of children with idiopathic short stature: a summary of the Growth Hormone Research Society, the Lawson Wilkins Pediatric Endocrine Society, and the European Society for Paediatric Endocrinology Workshop.J Clin Endocrinol Metab 2008, 93:4210–7. 10.1210/jc.2008-0509
Wit JM, Clayton PE, Rogol AD, Savage MO, Saenger PH, Cohen P: Idiopathic short stature: definition, epidemiology, and diagnostic evaluation.Growth Horm IGF Res 2008,18(2):89–110. 10.1016/j.ghir.2007.11.004
Rosenfeld RG, Hwa V: Toward a molecular basis for idiopathic short stature.J Clin Endocrinol Metab 2004,89(3):1066–7. 10.1210/jc.2004-0092
Wit JM, Kamp GA, Rikken B: Spontaneous growth and response to growth hormone treatment in children with growth hormone deficiency and idiopathic short stature.Pediatr Res 1996, 39:295–302.
Rekers-Mombarg LT, Wit JM, Massa GG, Ranke MB, Buckler JM, Butenandt O, et al.: Spontaneous growth in idiopathic short stature.European Study Group Arch Dis Child 1996,75(3):175–80. 10.1136/adc.75.3.175
Wit JM: Idiopathic short stature: reflections on its definition and spontaneous growth.Horm Res 2007,67(Suppl 1):50–7.
Price DA: Spontaneous adult height in patients with idiopathic short stature.Horm Res 1996,45(Suppl 2):59–63.
Ranke MB, Grauer ML, Kistner K, Blum WF, Wollmann HA: Spontaneous adult height in idiopathic short stature.Horm Res 1995,44(4):152–7. 10.1159/000184616
Leschek EW, Rose SR, Yanovski JA, Troendle JF, Quigley CA, Chipman JJ, et al.: Effect of growth hormone treatment on adult height in peripubertal children with idiopathic short stature: a randomized, double-blind, placebo-controlled trial.J Clin Endocrinol Metab 2004,89(7):3140–8. 10.1210/jc.2003-031457
McCaughey ES, Mulligan J, Voss LD, Betts PR: Randomised trial of growth hormone in short normal girls.Lancet 1998,351(9107):940–4. 10.1016/S0140-6736(05)60604-6
Albertsson-Wikland K, Aronson AS, Gustafsson J, Hagenäs L, Ivarsson SA, Jonsson B, et al.: Dose-dependent effect of growth hormone on final height in children with short stature without growth hormone deficiency.J Clin Endocrinol Metab 2008,93(11):4342–50. 10.1210/jc.2008-0707
López-Siguero JP, García-Garcia E, Carralero I, Martínez-Aedo MJ: Adult height in children with idiopathic short stature treated with growth hormone.J Pediatr Endocrinol Metab 2000,13(9):1595–1602.
Coutant R, Rouleau S, Despert F, Magontier N, Loisel D, Limal JM: Growth and adult height in GH-treated children with nonacquired GH deficiency and idiopathic short stature: the influence of pituitary magnetic resonance imaging findings.J Clin Endocrinol Metab 2001,86(10):4649–54. 10.1210/jcem.86.10.7962
Lopez-Siquero JP, Martínez-Aedo MJ, Moreno-Molina JA: Final height after growth hormone therapy in children with idiopathic short stature and a subnormal growth velocity.Acta Pediatr 1996, 85:113–47.
Hindmarsh PC, Brook CG: Final height of short normal children treated with growth hormone.Lancet 1996,348(9019):13–6. 10.1016/S0140-6736(96)01038-0
Wit JM, Rekers-Mombarg LT, Dutch Growth Hormone Advisory Group: Final height gain by GH therapy in children with idiopathic short stature is dose dependent.J Clin Endocrinol Metab 2002,87(2):604–11. 10.1210/jcem.87.2.8225
Buchlis JG, Irizarry L, Crotzer BC, Shine BJ, Allen L, MacGillivray MH: Comparison of final heights of growth hormone-treated vs. untreated children with idiopathic growth failure.The Journal of Clinical Endocrinology & Metabolism 1998,83(4):1075–9. 10.1210/jcem.83.4.4703
Christensen TL, Djurhuus CB, Clayton P, Christiansen JS: An evaluation of the relationship between adult height and health-related quality of life in the general UK population.Clin Endocrinol (Oxf) 2007, 67:407–12. 10.1111/j.1365-2265.2007.02901.x
Coste J, Pouchot J, Carel JC: Height and health-related quality of life: a nationwide population study.J Clin Endocrinol Metab 2012, 97:3231–9. 10.1210/jc.2012-1543
Theunissen NC, Kamp GA, Koopman HM, Zwinderman KA, Vogels T, Wit JM: Quality of life and self-esteem in children treated for idiopathic short stature.J Pediatr 2002,140(5):507–15. 10.1067/mpd.2002.123766
Radcliffe DJ, Pliskin JS, Silvers JB, Cuttler L: Growth hormone therapy and quality of life in adults and children.Pharmacoeconomics 2004, 22:499–524. 10.2165/00019053-200422080-00003
Sandberg DE, Brook AE, Campos SP: Short stature: a psychosocial burden requiring growth hormone therapy?Pediatrics 1994, 94:832–40.
Bullinger M: Psychological criteria for treating children with idiopathic short stature.Horm Res Paediatr 2011,76(Suppl 3):20–3.
Chaplin JE: Growth-related quality of life.Horm Res Paediatr 2011,76(Suppl 3):51–2.
Dunkel L, Wit JM: Developments in idiopathic short stature.Horm Res Paediatr 2011,76(Suppl 3):1–60.
Noeker M: Psychological functioning in idiopathic short stature.Horm Res Paediatr 2011,76(Suppl 3):52–6.
Rekers-Mombarg LT, Busschbach JJ, Massa GG, Dicke J, Wit JM: Quality of life of young adults with idiopathic short stature: effect of growth hormone treatment.Dutch Growth Hormone Working Group Acta Paediatr 1998,87(8):865–70.
Sandberg DE: Psychosocial aspects of short stature and its management: good deeds require good science.Horm Res Paediatr 2011,76(Suppl 3):37–9.
Sandberg DE, Bukowski WM, Fung CM, Noll RB: Height and social adjustment: are extremes a cause for concern and action?Pediatrics 2004,114(3):744–50. 10.1542/peds.2003-1169-L
Rosenbloom AL: Idiopathic short stature: conundrums of definition and treatment.Int J Pediatr Endocrinol 2009., 470378:
Voss LD: Growth hormone therapy for the short normal child: who needs it and who wants it? The case against growth hormone therapy.J Pediatr 2000,136(1):103–6. 10.1016/S0022-3476(00)90058-1
Ambler GR, Fairchild J, Wilkinson DJ: Debate: idiopathic short stature should be treated with growth hormone.J Paediatr Child Health 2013,49(3):165–9. 10.1111/j.1440-1754.2012.02465.x
Guyda HJ: Four decades of growth hormone therapy for short children: what have we achieved?J Clin Endocrinol Metab 1999,84(12):4307–16. 10.1210/jcem.84.12.6189
Rosenbloom AL: Pediatric endo-cosmetology and the evolution of growth diagnosis and treatment.J Pediatr 2011,158(2):187–93. 10.1016/j.jpeds.2010.10.004
Collett-Solberg PF: Update in growth hormone therapy of children.J Clin Endocrinol Metab 2011, 96:573–9. 10.1210/jc.2010-1131
Ranke MB: Treatment of children and adolescents with idiopathic short stature.Nat Rev Endocrinol 2013, 9:325–34. 10.1038/nrendo.2013.71
Finkelstein BS, Imperiale TF, Speroff T, Marrero U, Radcliffe DJ, Cuttler L: Effect of growth hormone therapy on height in children with idiopathic short stature: a meta-analysis.Arch Pediatr Adolesc Med 2002, 156:230–40. 10.1001/archpedi.156.3.230
Bryant J, Baxter L, Cave CB, Milne R: Recombinant growth hormone for idiopathic short stature in children and adolescents.Cochrane Database Syst Rev 2007, CD004440.
Deodati A, Peschiaroli E, Cianfarani S: Review of growth hormone randomized controlled trials in children with idiopathic short stature.Horm Res Paediatr 2011,76(Suppl 3):40–2.
Sotos JF, Tokar NJ: Growth hormone significantly increases the adult height of children with idiopathic short stature: comparison of subgroups and benefit.Int J Pediatr Endocrinol 2014,2014(1):15. 10.1186/1687-9856-2014-15
Loche S, Cambiaso P, Setzu S, Carta D, Marini R, Borrelli P, et al.: Final height after growth hormone therapy in non-growth-hormone-deficient children with short stature.J Pediatr125:196–2000.
Wit JM, Rekers-Mombarg LT, Cutler GB, Crowe B, Beck TJ, Roberts K, et al.: Growth hormone (GH) treatment to final height in children with idiopathic short stature: evidence for a dose effect.J Pediatr 2005, 146:45–53. 10.1016/j.jpeds.2004.08.055
Hintz RL, Attie KM, Baptista J, Roche A: Effect of growth hormone treatment on adult height of children with idiopathic short stature.Genentech Collaborative Group N Engl J Med 1999, 340:502–7.
Lee PA, Savendahl L, Oliver I, Tauber M, Blankenstein O, Ross J, et al.: Comparison of response to 2-years’ growth hormone treatment in children with isolated growth hormone deficiency, born small for gestational age, idiopathic short stature, or multiple pituitary hormone deficiency: combined results from two large observational studies.Int J Pediatr Endocrinol 2012, 2012:22. 10.1186/1687-9856-2012-22
Dahlgren J: Growth outcomes in individuals with idiopathic short stature treated with growth hormone therapy.Horm Res Paediatr 2011,76(Suppl 3):42–5.
Hopwood NJ, Hintz RL, Gertner JM, Attie KM, Johanson AJ, Baptista J, et al.: Growth response of children with non-growth-hormone deficiency and marked short stature during three years of growth hormone therapy. 1993.J Pediatr 1994, 123:215–22.
Hughes IP, Harris M, Choong CS, Ambler G, Cutfield W, Hofman P, et al.: Growth hormone regimens in Australia: analysis of the first 3 years of treatment for idiopathic growth hormone deficiency and idiopathic short stature.Clin Endocrinol (Oxf) 2012, 77:62–71. 10.1111/j.1365-2265.2011.04230.x
Van Gool SA, Kamp GA, Odink RJ, de Muinck Keizer-Schrama SM, de Waal HA D-v, Oostdijk W, et al.: High-dose GH treatment limited to the prepubertal period in young children with idiopathic short stature does not increase adult height.Eur J Endocrinol 2010, 162:653–60. 10.1530/EJE-09-0880
Cohen P, Germak J, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG: Variable degree of growth hormone (GH) and insulin-like growth factor (IGF) sensitivity in children with idiopathic short stature compared with GH-deficient patients: evidence from an IGF-based dosing study of short children.J Clin Endocrinol Metab 2010, 95:2089–98. 10.1210/jc.2009-2139
Cohen P, Weng W, Rogol AD, Rosenfeld RG, Kappelgaard AM, Germak J: Dose-sparing and safety-enhancing effects of an IGF-I-based dosing regimen in short children treated with growth hormone in a 2-year randomized controlled trial: therapeutic and pharmacoeconomic considerations.Clin Endocrinol (Oxf) 2014.
Cohen P, Rogol AD, Weng W, Kappelgaard AM, Rosenfeld RG, Germak J: Efficacy of IGF-based growth hormone (GH) dosing in nonGH-deficient (nonGHD) short stature children with low IGF-I is not related to basal IGF-I levels.Clin Endocrinol (Oxf) 2013, 78:405–14. 10.1111/cen.12014
Roche AF: The final phase of growth in stature.Growth, Genetics and Hormones 1989, 5:4–6.
Roche AF: Growth, Maturation and Body Composition. The Fels Longitudinal Study 1929–1991. Press CU; 1992. 104–106 and 132–138
Tanner JM, Whitehouse RH: Clinical longitudinal standards for height, weight, height velocity, weight velocity, and stages of puberty.Arch Dis Child 1976, 51:170–9. 10.1136/adc.51.3.170
Tanner JM, Whitehouse RH, Marubini E, Resele LF: The adolescent growth spurt of boys and girls of the Harpenden growth study.Ann Hum Biol 1976, 3:109–26. 10.1080/03014467600001231
Wit JM, Hero M, Nunez SB: Aromatase inhibitors in pediatrics.Nat Rev Endocrinol 2011, 8:135–47. 10.1038/nrendo.2011.161
Dunkel L: Update on the role of aromatase inhibitors in growth disorders.Horm Res 2009,71(Suppl 1):57–63.
Dunkel L: Use of aromatase inhibitors to increase final height.Mol Cell Endocrinol 2006, 254–255:207–16.
Shulman DI, Francis GL, Palmert MR, Eugster EA: Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development.Pediatrics 2008, 121:e975–83. 10.1542/peds.2007-2081
Mauras N: Strategies for maximizing growth in puberty in children with short stature.Endocrinol Metab Clin North Am 2009, 38:613–24. 10.1016/j.ecl.2009.06.004
Dunkel L: Off-label use of aromatase inhibitors to promote taller stature: is it safe.Horm Res Paediatr 2010, 74:436–7. 10.1159/000317434
Dunkel L: Treatment of idiopathic short stature: effects of gonadotropin-releasing hormone analogs, aromatase inhibitors and anabolic steroids.Horm Res Paediatr 2011,76(Suppl 3):27–9.
Diaz-Thomas A, Shulman D: Use of aromatase inhibitors in children and adolescents: what’s new?Curr Opin Pediatr 2010, 22:501–7. 10.1097/MOP.0b013e32833ab888
Geffner ME: For debate: Aromatase inhibitors to augment height: have we lost our inhibitions?Pediatr Endocrinol Rev 2008, 5:756–9.
Geffner ME: Aromatase inhibitors to augment height: continued caution and study required.J Clin Res Pediatr Endocrinol 2009, 1:256–61. 10.4274/jcrpe.v1i6.256
Wickman S, Sipilä I, Ankarberg-Lindgren C, Norjavaara E, Dunkel L: A specific aromatase inhibitor and potential increase in adult height in boys with delayed puberty: a randomised controlled trial.Lancet 2001, 357:1743–8. 10.1016/S0140-6736(00)04895-9
Hero M, Norjavaara E, Dunkel L: Inhibition of estrogen biosynthesis with a potent aromatase inhibitor increases predicted adult height in boys with idiopathic short stature: a randomized controlled trial.J Clin Endocrinol Metab 2005, 90:6396–402. 10.1210/jc.2005-1392
Hero M, Wickman S, Dunkel L: Treatment with the aromatase inhibitor letrozole during adolescence increases near-final height in boys with constitutional delay of puberty.Clin Endocrinol (Oxf) 2006, 64:510–3. 10.1111/j.1365-2265.2006.02499.x
Salehpour S, Alipour P, Razzaghy-Azar M, Ardeshirpour L, Shamshiri A, Monfared MF, et al.: A double-blind, placebo-controlled comparison of letrozole to oxandrolone effects upon growth and puberty of children with constitutional delay of puberty and idiopathic short stature.Horm Res Paediatr 2010, 74:428–35. 10.1159/000315482
Hero M, Toiviainen-Salo S, Wickman S, Mäkitie O, Dunkel L: Vertebral morphology in aromatase inhibitor-treated males with idiopathic short stature or constitutional delay of puberty.J Bone Miner Res 2010, 25:1536–43. 10.1002/jbmr.56
Mauras N, Welch S, Rini A, Klein KO: An open label 12-month pilot trial on the effects of the aromatase inhibitor anastrozole in growth hormone (GH)-treated GH deficient adolescent boys.J Pediatr Endocrinol Metab 2004, 17:1597–606.
Mauras N, Gonzalez de Pijem L, Hsiang HY, Desrosiers P, Rapaport R, Schwartz ID, et al.: Anastrozole increases predicted adult height of short adolescent males treated with growth hormone: a randomized, placebo-controlled, multicenter trial for one to three years.J Clin Endocrinol Metab 2008, 93:823–31. 10.1210/jc.2007-1559
Vincelet C, Tabone MD, Berthier M, Bonnefoi MC, Chevallier B, Lemaire JP, et al.: Le carnet de santé de l’enfant est-il informatif? Évaluation dans différentes structures de prévention et de soins.Arch Pediatr 2003,10(5):403–9. 10.1016/S0929-693X(03)00086-1
Greulich WaP S: Radiographic Atlas of Skeletal Development of Hand and Wrist. Stanford University Press; 1959.
O’Connor JE, Bogue C, Spence LD, Last J: A method to establish the relationship between chronological age and stage of union from radiographic assessment of epiphyseal fusion at the knee: an Irish population study.J Anat 2008, 212:198–209. 10.1111/j.1469-7580.2007.00847.x
Roche AF, Wainer H, Thissen D: The Knee Joint as a Biological Indicator. New York: Plenum Press; 1975.
Cohen P, Rogol AD, Howard CP, Bright GM, Kappelgaard AM, Rosenfeld RG: Insulin growth factor-based dosing of growth hormone therapy in children: a randomized, controlled study.J Clin Endocrinol Metab 2007, 92:2480–6. 10.1210/jc.2007-0204
Garn SM, Rohman CG, Apfelbaum B: Complete epiphyseal union of the hand.Am J Phys Anthropol 1961, 19:365–72. 10.1002/ajpa.1330190408
Shams K, Cameo T, Fennoy I, Hassoun AA, Lerner SE, Aranoff GS, et al.: Outcome analysis of aromatase inhibitor therapy to increase adult height in males with predicted short adult stature and/or rapid pubertal progress: a retrospective chart review.J Pediatr Endocrinol Metab 2014,27(7–8):725–30.
Durand-Zaleski I: Developments in idiopathic short stature: cost versus allocation of resources.Horm Res Paediatr 2011,76(Suppl 3):33–5.
Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B: Long-term safety of recombinant human growth hormone in children.J Clin Endocrinol Metab 2010, 95:167–77. 10.1210/jc.2009-0178
Quigley CA, Gill AM, Crowe BJ, Robling K, Chipman JJ, Rose SR, et al.: Safety of growth hormone treatment in pediatric patients with idiopathic short stature.J Clin Endocrinol Metab 2005,90(9):5188–96. 10.1210/jc.2004-2543
Rosenfeld RG, Cohen P, Robison LL, Bercu BB, Clayton P, Hoffman AR, et al.: Long-term surveillance of growth hormone therapy.J Clin Endocrinol Metab 2012,97(1):68–72. 10.1210/jc.2011-2294
Kemp SF, Kuntze J, Attie KM, Maneatis T, Butler S, Frane J, et al.: Efficacy and safety results of long-term growth hormone treatment of idiopathic short stature.J Clin Endocrinol Metab 2005,90(9):5247–53. 10.1210/jc.2004-2513
Savendahl L, Maes M, Albertsson-Wikland K, Borgstrom B, Carel JC, Henrard S, et al.: Long-term mortality and causes of death in isolated GHD, ISS, and SGA patients treated with recombinant growth hormone during childhood in Belgium, The Netherlands, and Sweden: preliminary report of 3 countries participating in the EU SAGhE study.J Clin Endocrinol Metab 2012, 97:E213–7. 10.1210/jc.2011-2882
De Ronde W, de Jong FH: Aromatase inhibitors in men: effects and therapeutic options.Reprod Biol Endocrinol 2011, 9:93. 10.1186/1477-7827-9-93
Raven G, de Jong FH, Kaufman JM, de Ronde W: In men, peripheral estradiol levels directly reflect the action of estrogens at the hypothalamo-pituitary level to inhibit gonadotropin secretion.J Clin Endocrinol Metab 2006, 91:3324–8. 10.1210/jc.2006-0462
T’Sjoen GG, Giagulli VA, Delva H, Crabbe P, De Bacquer D, Kaufman JM: Comparative assessment in young and elderly men of the gonadotropin response to aromatase inhibition.J Clin Endocrinol Metab 2005, 90:5717–22. 10.1210/jc.2005-0982
Hero M, Ankarberg-Lindgren C, Taskinen MR, Dunkel L: Blockade of oestrogen biosynthesis in peripubertal boys: effects on lipid metabolism, insulin sensitivity, and body composition.Eur J Endocrinol 2006, 155:453–60. 10.1530/eje.1.02226
Jolliffe CJ, Janssen I: Distribution of lipoproteins by age and gender in adolescents.Circulation 2006, 114:1056–62. 10.1161/CIRCULATIONAHA.106.620864
Wickman S, Kajantie E, Dunkel L: Effects of suppression of estrogen action by the p450 aromatase inhibitor letrozole on bone mineral density and bone turnover in pubertal boys.J Clin Endocrinol Metab 2003, 88:3785–93. 10.1210/jc.2002-021643
Hero M, Makitie O, Kroger H, Nousiainen E, Toiviainen-Salo S, Dunkel L: Impact of aromatase inhibitor therapy on bone turnover, cortical bone growth and vertebral morphology in pre- and peripubertal boys with idiopathic short stature.Horm Res 2009, 71:290–7. 10.1159/000208803